Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatment
Baseline serum levels of C2 and C3, as well as their variations pre- and post-treatment, may serve as biomarkers for predicting clinical efficacy in patients with first-episode SCZ undergoing treatment with aripiprazole.
Authors
- Qingrong Xia (ORCID: https://orcid.org/0000-0002-5941-5011)
- Yin Cao (ORCID: https://orcid.org/0000-0001-9835-7662)
- Biao Dai (ORCID: https://orcid.org/0009-0000-0463-421X)
- Jun Liang (ORCID: https://orcid.org/0000-0003-0848-5658)
- Feng Shan
Institutions
- Anhui Medical University (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Anhui Mental Health Center (CN)
- Hefei Infectious Disease Hospital (CN)
Publication Details
- Journal
- BMC Psychiatry
- Published
- 2024-12-31
- DOI
- https://doi.org/10.1186/s12888-024-06437-0
- Citations
- 2
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- Anhui Medical University